CytoSorbents Corporation (CTSO)

[biotech48]

“These potassium binding polymers represent an entirely new product category for the company. They leverage the massive surface area of our existing hemocompatible porous polymers with robust potassium binding technology to target rapid and sustained potassium reduction without the need for complicated dialysis,” said Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents. “Our goal is to provide field medics with easy-to-administer solutions to acutely treat and stabilize wounded warfighters suffering from severe hyperkalemia as a result of massive trauma, burn injury, kidney failure, blood transfusions, and other conditions. These strategies could enable prolonged field care, particularly in far-forward situations where rapid evacuation is neither safe nor feasible. As a simpler, more rapid, and logistically friendly alternative to dialysis, we also envision our technology being used in emergency room or hospitalized patients with severe hyperkalemia, and helping victims of bombings, earthquakes, landslides and other mass casualty situations.”
https://cytosorbents.com/cytosorbents-awarded-650000-in-sbir-grant-contracts-to-continue-development-of-novel-hemocompatible-potassium-binding-polymers/